Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

746
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
746
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

415
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
415
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

6.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biobased and Biodegradable Furandicarboxylate Polyesters: Linking Molecular Structure to Enzymatic Hydrolyzability.

Environmental science & technology·2026
Same author

Concerns regarding methodology, evidentiary basis, and potential industry-related influence in a recent American Association for Thoracic Surgery Expert Consensus Document.

The Journal of thoracic and cardiovascular surgery·2026
Same author

Implementing custom PRO and NPS tools in private practice: balancing simplicity and clinical value in a retrospective study.

Journal of patient-reported outcomes·2026
Same author

Zentralblatt fur Chirurgie·2026
Same authorSame journal

The Use of Intra-Aortic Balloon Pumping in Cardiac Surgery.

The Thoracic and cardiovascular surgeon·2026
Same author

The Role of Patients' Treatment Expectations in Ventricular Assist Device Support: Results From a Convergent Mixed Methods Study.

Artificial organs·2026
Same journal

Long-Term Redo CABG Outcomes: Propensity-Matched On-Pump vs Off-Pump Comparison.

The Thoracic and cardiovascular surgeon·2026
Same journal

PULMONARY ENDARTERECTOMY IN PEDIATRIC PATIENTS: INSTITUTIONAL EXPERIENCE.

The Thoracic and cardiovascular surgeon·2026
Same journal

Surgical Repair of Acquired Ventricular Septal Defects: Outcomes and Quality of Life.

The Thoracic and cardiovascular surgeon·2026
Same journal

Conflicts of Interest-From "Jein" to Transparency.

The Thoracic and cardiovascular surgeon·2026
Same journal

Beyond the Sternum: Reframing the Hidden Cost of Delayed Closure in Cardiac Surgery.

The Thoracic and cardiovascular surgeon·2026
See all related articles

Related Experiment Video

Updated: Apr 29, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.3K

Risk Reduction by Direct Thrombin Antagonism During ECMO Therapy.

Susanne Rohrbach1, Maurice Himmel2, Melanie Spaenig2

  • 1Institute of Physiology, Justus-Liebig-Universitat Giessen, Giessen, Hessen, Germany.

The Thoracic and Cardiovascular Surgeon
|April 27, 2026
PubMed
Summary
This summary is machine-generated.

Direct thrombin antagonism (DTA) is a safe and effective alternative to heparin for patients on extracorporeal membrane oxygenation (ECMO). DTA demonstrated non-inferiority and superiority in reducing complications and bleeding events.

More Related Videos

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

25.1K
Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting
08:53

Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting

Published on: March 28, 2025

828

Related Experiment Videos

Last Updated: Apr 29, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.3K
Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

25.1K
Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting
08:53

Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting

Published on: March 28, 2025

828

Area of Science:

  • Cardiology
  • Intensive Care Medicine
  • Pharmacology

Background:

  • Heparin-induced thrombocytopenia Type II (HITII) is a risk for ECMO patients.
  • Direct thrombin antagonism (DTA) lacks approval but is being investigated as an alternative.
  • This study assesses DTA's feasibility, safety, and efficacy compared to heparin.

Purpose of the Study:

  • To evaluate if direct thrombin antagonism (DTA) is a feasible, safe, and non-inferior alternative to heparin in ECMO patients.
  • To compare DTA with heparin regarding anticoagulation stability, bleeding, thrombosis, and survival rates.
  • To determine DTA's superiority in reducing overall complications and specific adverse events.

Main Methods:

  • A prospective, multicenter study analyzed 254 patients (vv- or va-ECMO) across four university hospital ICUs.
  • Patients received either heparin, DTA, or switched from heparin to DTA due to suspected HITII.
  • Outcomes including ICU morbidity, survival, anticoagulation stability, bleeding, and thrombosis were analyzed.

Main Results:

  • No significant difference in thrombosis or system occlusions between heparin and DTA.
  • DTA showed non-inferiority in weaning rates from extracorporeal support and survival.
  • DTA demonstrated superiority in overall complication rates (including bleeding, stroke, amputation, thrombosis) and bleeding events alone.

Conclusions:

  • Direct thrombin antagonism (DTA) is non-inferior to heparin in extracorporeal life support/ECMO therapy.
  • DTA is superior to heparin in reducing overall complications, stroke, thromboembolism, and amputation.
  • DTA presents a promising alternative anticoagulation strategy for ECMO patients.